Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids

Table 2 Risk allele frequency of rs10911021 for UCLEB participants

	BRHS	BWHHS	CAPS	EAS	ELSA	ET2DS	MRC1946	WHII	Combined
No T2D
MAF no CHD	0.30 (1544)	0.32 (1528)	0.31 (1022)	0.31 (553)	0.30 (1426)	–	0.32 (2294)	0.31 (2851)	0.31 (8665)
MAF CHD	0.30 (378)	0.31 (285)	0.28 (239)	0.29 (132)	0.29 (114)	–	0.31 (65)	0.35 (161)	0.30 (1677)
OR (95 % CI)	1.02 (0.85–1.22)	1.01 (0.79–1.28)	0.82 (0.65–1.04)	0.90 (0.67–1.23)	1.10 (0.81–1.49)	–	1.00 (0.68–1.47)	1.23 (0.97–1.56)	1.00 (0.92–1.10)
p value	0.81	0.94	0.10	0.64	0.54	–	0.43	0.09	0.93
T2D
MAF no CHD	0.31 (190)	0.34 (94)	0.30 (20)	0.23 (46)	0.32 (160)	0.30 (793)	0.28 (45)	0.31 (29)	0.30 (1377)
MAF CHD	0.18 (72)	0.20 (13)	0.29 (16)	0.24 (13)	0.29 (7)	0.32 (31)	0.40 (5)	0.30 (3)	0.26 (160)
OR (95 % CI)	0.44 (0.26–0.74)	0.48 (0.17–1.33)	1.43 (0.51–4.00)	1.05 (0.36–3.03)	0.85 (0.25–2.94)	1.35 (0.80–2.33)	1.69 (0.46–6.25)	1.01 (0.52–1.96)	0.80 (0.60–1.06)
p value	2 × 10⁻³	0.16	0.49	0.95	0.80	0.26	0.43	0.87	0.13

Minor allele frequency RAF is shown separately for those who did and did not go on to develop CHD. n is shown in brackets. The odds ratio (OR) adjusted for sex for the association between rs10911021 and CHD in T2D is also shown with its 95 % confidence intervals (95 % CI)

ISSN: 1475-2840